Coherence Neuro Funding Round

10/22/2026

Venture Equity

$45,000,000

Series A

The company intends to use the funds to advance toward its first chronic human clinical trial in glioblastoma, seek an official FDA breakthrough device designation, expand its preclinical research and development pipeline into pancreatic cancer and other indications, and grow its cross-disciplinary team of hardware builders and operators.

Private & Independent

Medical Devices & Instruments

Undisclosed
San Francisco, CA Undisclosed
USA

Undisclosed

Coherence operates at the intersection of neurotechnology, neurobiology, and machine learning. Our mission is to improve quality and length of life for people with cancer. For decades, cancer treatment has remained largely unchanged -- we cut it, we burn it, we poison it. These methods, while in some ways effective, come at a tremendous cost to the patient's health, quality of life, and emotional well-being.? At Coherence, we believe there's a better way. We are leading a revolution in cancer treatment, transforming it from a brutal battle into a continuously monitored and seamlessly managed condition.